S4
High-resolution mass spectrometry data were collected with a Waters LCT Premier XE time-offlight instrument controlled by MassLynx 4.1 software or obtained on a Thermo Scientific™ Exactive Mass Spectrometer with DART ID-CUBE. Samples were dissolved in methanol and infused using direct loop injection from a Waters Acquity UPLC into the Multi-Mode Ionization source. HPLC purifications were performed on a Knauer Smartline HPLC system with inline Knauer UV (254 nm) detector. Semi-preprative HPLC was performed using Phenomenex reversephase Luna column (10 × 250 mm, 5 µm) with a flow rate of 4 mL/min. Final purity of compounds was determined by analytical HPLC analysis performed with a Phenomenex reverse-phase Luna column (4.6 × 250 mm, 5 µm) with a flow rate of 1 mL/min. Compounds were identified by UV absorbance at 254 nm. All chromatograms were collected by a GinaStar (raytest USA, Inc.;
Wilmington, NC, USA) analog to digital converter and GinaStar software (raytest USA, Inc.).
Experimental Data

Synthesis and characterization of the tri-functional platform (TFP)
Intermediates 1a and 2 were synthesized according to literature procedure. [3] (S)-19-((tert-butoxycarbonyl)amino)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,13-dioxo-7,10-dioxa-4,14-diazaicosan-20-oic acid (1a). A 10 mL round bottom flask equipped with a stir bar and filled with argon, was charged with N-Boc-L-lysine (61 mg, 0.248 mmol, 1.1 equiv) and dry DMF (1 mL). To this, N,N-diisopropylethylamine (86 µL, 0.495 mmol, 2.5 equiv) was added and the mixture was stirred at room temperature for 1 h. Malamido-PEG2-NHS (100 mg, 0.23 mmol, 1.0 equiv) then was added and the reaction mixture was stirred at room temperature until full consumption of starting materials was indicated by TLC. DMF was removed under reduced pressure and the crude mixture was purified by flash column chromatography on silica gel (5% MeOH in DCM to 10% MeOH in DCM) to give 100 mg of the desired product as a colorless oil (78% yield). Purified 1a was stored under argon at -20°C. 1 H and 13 C NMR spectroscopic data were consistent with previously reported values. [3] HRMS (ESI) m/z calcd for C25H40N4O10 [M + H] + , 557.2817, found 557.2847.
Tert-butyl (S)-(22-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1-(4-(6-methyl-1,2,4,5-tetrazin-3yl)phenyl)-3,10,20-trioxo-13,16-dioxa-2,9,19-triazadocosan-4-yl)carbamate (2). To a solution of 1a (60 mg, 108 µmol, 1.0 equiv) in DMF (1.2 mL) was added HATU (46 mg, 119 µmol, 1.1 equiv) and the mixture was stirred for 10 min at room temperature. To this, a solution of 4-(6methyl-1,2,4,5-tetrazin-3-yl)benzyl amine [1] (76 mg, 319 µmol, 2.96 equiv) in DMF (1.5 mL) was added and the mixture was stirred for another 20 min. N,N-diisopropylethylamine (54 µL, 313 µmol, 2.9 equiv) was added and the mixture was stirred at room temperature for 36 hours. DMF was removed under reduced pressure and the crude mixture was purified by flash column chromatography on silica gel (0% to 10% MeOH in DCM) to give 49 mg of the desired product as a deep purple oil (71% yield). Characterization data were consistent with previously reported data. [3] ESI was removed and the crude residue was subjected to semi-preparative HPLC purification. [3] The fraction containing the product was lyophilized yielding 19 mg of desired compound as a purple solid (40 % yield). Due to instability issues, the intermediate was immediately conjugated to commercial DOTA-NHS ester. To a 1.5 mL Eppendorf tube was added 3 (3.6 mg, 5.32 µmol, 1 equiv) and dry DMF (0.16 mL). To this, triethylamine (7.4 µL, 53.2 µmol, 10 equiv) was added and the mixture was stirred at room temperature for 15 min. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-N-hydroxysuccinimide ester (4 mg, 5.32 µmol, 1 equiv) was added and the reaction mixture was stirred at room temperature for 16 hours. DMF was removed under reduced pressure and the residue was subjected to semi-preparative HPLC purification to afford 2.7 mg of the tri-functional platform 3 as a dark purple solid (49% yield). 
Construction and characterization of the modular cys-diabody, TFP-cDb
Generation and production of the anti-PSCA cys-diabody 2B3 A2 (cDb) were described previously. [4] Site-specific conjugation was performed as previously described [3] . Briefly, the protein was dissolved in PBS pH 7.4 and incubated with tris-(2-carboxyethyl)phosphine, hydrochloride (TCEP, 10-fold molar excess) for 30 min at room temperature to reduce the Cterminal cystine disulfides. Following reduction, a solution of 3 in DMF (3-to 10-fold molar excess) was added to the reduced protein and the reaction was incubated for 2 h at room temperature. Excess reagents were separated from the protein conjugate using Micro Bio-Spin size exclusion columns (BioRad) pre-blocked with PBS, 1%FBS. The modular cys-diabody TFP-cDb was analyzed by polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion chromatography (SEC) using a Superdex-75 HR10/30 column in an Äkta purifier (GE Healthcare).
The interchain disulfide bond provides the stabilizing force for the cys-diabody dimer which, following reduction, is merely held together by weak non-covalent interactions. Therefore, in SDS-PAGE, the nonreduced anti-PSCA A2 cys-diabody migrates as a 50 kDa dimeric band, whereas the completely reduced protein migrates as a 25 kDa monomeric band. Upon reduction, the free cysteines can undergo a Michael addition with 3, forming a stable thioether linkage and preventing dimer formation via the interchain disulfide bond. Thus, the monomeric band in Figure S3 confirms successful conjugation of 3 to afford the modular cys-diabody TFP-cDb. To evaluate the purity and integrity of TFP-cDb, size exclusion chromatography was conducted (Figure S3 ).
Both the unconjugated protein cDb and the conjugated protein TFP-cDb elute with similar retention times indicating that protein reduction and conjugation to compound 3 did not impede dimer formation. 
Radiochemistry
General materials and methods
Synthesis of [ 18 F]fluoroethoxy TCO
[ 18 F]fluoroethoxy TCO was synthesized with the ELIXYS FLEX/CHEM radiosynthesizer (Sofie Biosciences) and reformulated in 0.5% aq. sodium ascorbate:DMSO solution, 1:1 (v/v) as reported previously. [2] 6. Positron Emission Tomography (PET) Imaging
18 F-Labeling of the modular cys-diabody, TFP-cDb, to afford 18 F-cDb
TFP-cDb was incubated with [ 18 F]fluoroethoxy TCO (37 MBq) at room temperature for 10 minutes to afford the (4 + 2) cycloaddition product, 18 F-cDb. 18 F-cDb was purified using Micro Bio-spin columns. Radiochemical purity and labeling efficiency was determined by ITLC (ITLC strips for monoclonal antibody preparation, Biodex Medical Systems). Samples were spotted at the origin and developed in acetonitrile as the solvent. The ITLC strips were cut in half and gamma counted in a Wizard 3' 1480 Automatic Gamma Counter (Perkin Elmer).
Immunoreactivity Measurement
The percentage of immunoreactive 18 F-cDb was measured by incubating approximately 0.5 ng of radiolabeled protein with excess (30-45 x 10 6 ) human PSCA-expressing prostate cancer cells S11 (22Rv1-PSCA) in PBS/1% FBS for 1 h at room temperature. Cells were centrifuged and radioactivity was counted in a gamma counter. The immunoreactive fraction was calculated as the percentage of cell bound activity in the pellet over total activity (pellet plus supernatant).
Prostate cancer xenograft mouse model (22Rv1-PSCA)
All procedures involving animals were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (USA), under protocols approved by the UCLA Chancellor's Animal Research Committee. Cell lines 22Rv1 and 22Rv1-PSCA were previously described [5] and were cultured in RPMI1640, 10% FBS. Tumors were inoculated subcutaneously (1x10 6 cells/100 µL in 1:1 PBS:Matrigel (BD Biosciences)) in the shoulder of male nude mice (8-12 weeks, JAX002019, Jackson Laboratories) as previously described. [6] 
In vivo microPET/CT imaging
ROI analysis and ex vivo biodistribution
PET image analysis was performed using AMIDE. [7] Quantitative region of interest (ROI) analysis was performed by converting the mean voxel value to percent injected dose per gram (%ID/gROI, assuming a tissue density of 1 g/mL) using the decay-corrected injected dose. Following the final scans, mice were euthanized and ex vivo biodistribution analysis was performed. Major organs and tissues were dissected, weighed and the radioactivity was measured using a gamma counter.
The percent-injected dose per gram of tissue (%ID/g) was calculated using a standard containing 1% of the injected dose. Radioactivity in the kidneys saturated the count-rate capacity of the gamma counter (Table S1) TFP-cDb was incubated with sCy5-TCO at room temperature for 10 minutes to afford the (4 + 2) cycloaddition product, sCy5-cDb. Following procedures described above, excess label was removed using Micro Bio-spin columns and sCy5-cDb was analyzed by SDS-PAGE and SEC (Figure S5) . Dye and protein concentrations were measured using a spectrophotometer at 650 nm and 280 nm, respectively and the dye:protein ratio was determined to be 1.1. 
In vivo NIRF imaging in tumor-bearing mice
Optical imaging was conducted post mortem with the skin removed or of dissected tumors and organs ex vivo using the IVIS Lumina II system (PerkinElmer) with settings: 675 ex/694 em (Cy5.5) and 5 sec exposure time. Living Image Software (IVIS Imaging Systems, PerkinElmer) was used to display fluorescence/visible light overlays. Figure. Site-specific conjugation of purified cDb with TFP followed by (4+2) cycloaddition reaction with sCy5-TCO to afford the fluorescently labeled diabody, sCy5-cDb. Size exclusion chromatography was conducted to evaluate purity and integrity of sCy5-cDb. Successful labeling with sCy5 was achieved without interfering with the dimeric conformation of the diabody. 
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